Adverse Events
The Ablatherm HIFU treatment provides a safe, effective, minimally invasive treatment for prostate cancer with minimal morbidity.
| Death | 0% |
| Rectal wall burn | 0% |
| Haemorrhoidal pain | 0% |
| Stress urinary incontinence | |
| Grade I (average 27 days) | 9% |
| Grade II (average 32 days) | 2% |
| Grade III | 1% |
| Urgency | 7% |
| Urge incontinence | 0% |
| UTI’s | 13% |
| Significant Haematuria | 0% |
| Erectile dysfunction / Nerve Sparing | 22% |
| Erectile dysfunction / Non-nerve sparing | 66% |
| Since 2002 Prostato-rectal fistulae | 0% |
Reference
1) High-Intensity Focused Ultrasound for the treatment
of localised prostate cancer: Efficacy results
from the European Multicentric Study. S Thuroff, C Chaussy G. Vallancien
et al. J Endourol,
Vol 17, 8, Oct 2003
